Core Viewpoint - BioRestorative Therapies, Inc. is set to release its second quarter 2025 financial results on August 12, 2025, followed by a conference call for a business update [1][2]. Company Overview - BioRestorative Therapies, Inc. focuses on developing therapeutic products using adult stem cells, with two main clinical development programs targeting disc/spine disease and metabolic disorders [3]. - The company operates a commercial BioCosmeceutical platform, offering products designed to reduce cosmetic signs of aging [5]. Clinical Development Programs - **Disc/Spine Program (brtxDISC™)**: The lead candidate, BRTX-100, is derived from a patient's own mesenchymal stem cells and aims to treat painful lumbosacral disc disorders. A Phase 2 clinical trial is underway for chronic lower back pain due to degenerative disc disease, with FDA IND clearance obtained for chronic cervical discogenic pain [3]. - **Metabolic Program (ThermoStem)**: This program focuses on using brown adipose-derived stem cells to develop therapies for obesity and metabolic disorders. Initial research suggests that increased brown fat may enhance caloric burning and lower glucose and lipid levels, potentially reducing obesity and diabetes risk [4]. BioCosmeceuticals - The company has a commercial BioCosmeceutical platform that includes a cell-based secretome product aimed at improving cosmetic appearance. Future plans involve expanding the product line to include more cell-based aesthetic products and therapeutics [5].

Core Viewpoint - BioRestorative Therapies, Inc. is set to release its first quarter 2025 financial results on May 14, 2025, followed by a conference call for a business update [1][2]. Company Overview - BioRestorative Therapies, Inc. focuses on developing stem cell-based therapies and products, primarily targeting disc/spine diseases and metabolic disorders [3]. - The company operates a commercial BioCosmeceutical platform, offering products that utilize cell and tissue protocols, particularly adult stem cells [3]. Clinical Development Programs - **Disc/Spine Program (brtxDISC™)**: The lead candidate, BRTX-100, is derived from a patient's own mesenchymal stem cells and is intended for non-surgical treatment of lumbosacral disc disorders. A Phase 2 clinical trial is underway for chronic lower back pain due to degenerative disc disease, with FDA IND clearance obtained for chronic cervical discogenic pain [3]. - **Metabolic Program (ThermoStem®)**: This program aims to develop therapies targeting obesity and metabolic disorders using brown adipose-derived stem cells (BADSC) to generate brown adipose tissue (BAT). Initial research suggests that increased brown fat may enhance caloric burning and lower glucose and lipid levels, potentially reducing obesity and diabetes risk [4]. BioCosmeceuticals - The company has a commercial BioCosmeceutical platform that includes a cell-based secretome product designed to reduce fine lines and wrinkles. Future plans involve expanding the product line to include more cell-based aesthetic products and therapeutics, with the goal of obtaining FDA approvals [5].